DIGIPHARM has built the world’s first blockchain-based platform for value-based contracting of healthcare technologies and healthcare services, where a service or a product is priced according to the benefits it provides to a consumer. DIGIPHARM’s vision is to be ‘the pioneer of value-based healthcare delivery, innovative evidence generation and patient empowerment across the healthcare industry’ using blockchain technology.
DIGIPHARM utilizes blockchain technology to overcome key infrastructural limitations to innovative pricing and evidence generation. Through the platforms provided by the project (REIMBURSE, INSIGHTS, DIGIHEALTH), the problems of current healthcare industry resulting in inefficiency, wastage and sub-optimal health outcomes for the patient will be tackled and solved. DIGIPHARMs’ platforms drive value improvement, reward innovation and expedite the transformation to value-based, personalised healthcare.
Utilizing blockchain technology for DIGIPHARMs’ platforms, the project aims to develop a decentralized health information infrastructure that is ubiquitous, transparent and security conscious. The project proposes that the development, maintenance and use of DIGIPHARM platforms will be subject to comprehensive data protection and security, advanced privacy measures and full conformance with the information governance protocols, including EU General Data Protection Regulation (EU GDPR).
The REIMBURSE platform will harness the beneficial features of automated ‘smart contracts’, allowing the real time application of flexible pricing models and patient access schemes between healthcare providers, payers and manufacturers.
The INSIGHTS platform will extract anonymised patient level data from the REIMBURSE platform and electronic patient records to the world’s first ‘live’ real-world evidence (RWE) database, that is accessible by subscribed users at real time.
The DIGIHEALTH platform will utilize data from the INSIGHTS database to generate a patient-friendly portal for sharing and utilizing health-related information on a global scale for the benefit of fellow patients, wider society and health systems worldwide.
Patients will be incentivized and rewarded for sharing and contributing their health-related data to populate the INSIGHTS and DIGIHEALTH platforms, if they so choose. There are also additional future projects, such as MYHEALTH and EVOLVE, that are planned to be implemented depending on permissibility under applicable laws.
DIGIPHARM modules will be designed with cross-platform and interblockchain compatibility, using the following benefits of using private blockchain technology: Security, confidentiality, scalability, smart contract execution.
The DIGIPHARM network will be fuelled by an ERC20 Ethereum minted token (DPH), which is used as a mechanism to monetize transactions and incentivize participants. A trusted & private network for entities participating in value-based agreements is built on Hyperledger Fabric v1.1.
Additional Features Across Platforms are as follows: Analytics Hub, Phone Apps & IoT, Sub-chains or Temporary Chains, Patient incentives
DIGIPHARM will be carrying out a pre-sale at Coineal Launchpad starting on May the 29th 03:00 (UTC) and ending on May the 30th 15:00 (UTC). Users, who would like to participate in the DIGIPHARM Pre-sale, need to register an account on Coineal Exchange.
The details of the Pre-Sale are as follows:
Token Name: Digipharm (DPH)Pre-Sale Date: May 29, 2019 at 03:00 (UTC) – May 30, 2019 at 15:00 (UTC)Pre-Sale Price: 1 DPH = $ 0.10 (paid in BTC)Tokens for Sale: 15,000,000 DPH
The native token for the Worldwide meds platform is the WDMD token, an ERC-20 compatible utility token with a limited maximum supply of 500,000,000 WDMD that can be obtained during the presale and public sale round of our ICO. It can be stored on any ERC-20 compatible wallets including on the Worldwide Meds platform. WDMD tokens will be listed and tradable on top exchanges 30 days after the public round of our ICO. WDMD tokens will be used to pay for all services within the Worldwide Meds Ecosystem and also be used to reward our active contributors, partners, patients, doctors and other healthcare providers via a profit sharing system integrated on the platform. All healthcare service providers registered on our platform will be remunerated in WDMD tokens which can be withdrawn to any ERC-20 compatible wallets and will be tradable on various top crypto exchanges. WDMD Coin is a Blockchain protocol for Telehealth and telemedicine. Through our smart contract feature, WDMD Coin will enable users in the third world countries to have access to doctors around the world 24 hours a day and 7 days a week for specialist advice. The implementation of our project will be fully based on a decentralized network. We strongly believe that the WDMD coin will help put an end to most of the challenges currently bedevilling the health sector with the help of blockchain technology.
This project aims to build an ecosystem that users get benefits from maintaining a healthy body, in addition to being healthy. Our mobile application, connected with the smart wearable devices, collect health information to claim token award from our token store. Users can claim rewards from us and our partners using the token. In later phrase, being healthy becomes a mining activity. mHealthCoin, an ERC-20 compatible coin, is awarded when users keep healthy habits, like drinking water, sleeping well, exercising, with our mobile applications. The coin will be well recognized by different parties internationally as the project advances.
Biohal is a decentralized preventive medicine platform that extensively uses liquid biopsy authentication protocol to detect Cancer and Alzheimer’s at early stages. Biohal’s mission is to create a universally available preventive medicine platform that runs on blockchain with liquid biopsy protocol. By joining hands with PROTEO, the first liquid biopsy research partner, Biohal can detect cancer and alzheimer’s at early stages. With minimally invasive markers, Biohal’s test accuracy remains at 99%.
MediConnect is the only blockchain solution intended to revolutionize the use of medication in the UK. It will prevent the over-prescribing to patients of medication from multiple pharmacies, reduce addiction, provide traceability of drugs from manufacturers, wholesalers, prescribers and pharmacies all the way through to patients. This will enable the removal of false medicines and the easy recall of drugs within the Pharma system. The Safety Net for Patients, Prescribers, Pharmacies and Drug Manufacturers: With all the regulatory bodies within the Pharmacy sector recognizing and concerned about the growing issue of over-prescribing of prescription medication online, MediConnect can offer a solution to this growing problem almost immediately. Prescribers & pharmacies using MediConnect will have the confidence that by using our blockchain solution, the misuse and over-prescribing of prescription medication to potential addicts – who would normally shop around online for medication – will be eliminated. Patients will be given the assurance that the medication they are being prescribed is genuine and from a licensed manufacturer, prescriber and pharmacy that is using a gold-standard solution to help improve their own duty of care.
CUREStoken has been forged out of a desire to help address this problem, by decentralizing the health care system, empowering patients, Health App developers, Medical Service Providers and Equipment Suppliers, embracing innovative technology in order to reduce costs and maximize scarce resources within the sector, creating near virtual competition, capitalizing on synergy which in turn adds value to all relevant stake holders.
Our vision of managing this change is to empower all stakeholders through the use of innovative technology such as blockchain and smart contracts. We see this resulting in more options and choices; transcending borders through medical tourism, nurturing a transparent and trusted review system,
allowing better and more informed decisions.
This makes CUREStoken a universal ecosystem of services available to all – patients, healthcare providers and those working in the field of medical tourism, by offering a combination of unique features including payment and settlement at minimum cost, unrivalled business opportunities including selling en-masse, fundraising interest free, trading contracts for future work (medical futures), storing and trading with medical records, digital health-aiding apps, as well as an element of corporate social responsibility through the charitable trust fund.
MEDoctor wants to provide its services to any patient worldwide. Everyone deserves proper healthcare, including in developing countries and in remote areas, where healthcare in not easily accessible.
MEDoctor has developed an artificial intelligence for diagnosis (which is free for worldwide usage). Based on the company’s proprietary 27,560 case study, the MEDoctor AI includes 898 diseases and conditions covering over 99 % of visits primary care physicians. A patient may initiate a diagnosis (DDx), helping them to make the appropriate decision regarding their ailment. They can also obtain a diagnosis for another person. It is accessible 24/7/365 worldwide.
One of the immediate choices offered to the patient is to speak with a physician via his / her smartphone. In MEDoctor’s network, online doctors, by video can advise the patient, without the patient needing wait several days for a consultation.
MedApp UK Ltd is an official provider and distributor of MedApp SA technology called Analytical telemedicine system CarnaLife. Medapp UK Ltd is also the official entity involved in the preparation and execution of the ICO project.
Cura Network is a global decentralized health system comprising of entities collaborating and sharing data with each other to promote, restore or maintain health. These entities are patients, specialists, providers, and third-party app developers. Patients will have exclusive ownership of their health data distributed and shared by other permissions entities. Patients can authorize or deny access to part or all of their health records. Cura Network introduces a decentralized storage of health data via a platform that guarantees data interoperability, fast and secure access, privacy and data portability while serving as a partial or whole data layer for third-party app developers to power their health service applications. Cura Network unites patients, specialists, researchers, insurance companies, developers etc. into a large global community.
The Zenome project is a decentralized blockchain-driven database of genomic information. This platform supports the possibility to manage your genomic data while maintaining privacy and ability to make a profit from selling access to different parts of the genome. It will establish equal conditions for drug development and for the progress of scientic and medical technologies.
Trade Pharma Network is a EU-Licensed marketplace of choice for buyers & sellers performing routine transactions of medicines. We also offers a full suite of pharma-centric services & solutions relating to Supply Chain, Outplacement, Charity etc. Indeed, we help pharma & healthcare organizations to establish and maintain business contacts, to generate new customers & trading partners and thus to participate in this World of Pharma & Healthcare Business 4.0.
Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs. Connecting patients directly to medical research and incentivizing them to share their data with tokens, blockchain is the decentralized technology everyone was waiting for to move away from the current linear process of drug approvals, to a new iterative model where trustworthy digital health data is shared in real time between patients, life sciences and regulators. The 21st Century Cures Act (2016) gave the FDA a mandate to accelerate approvals if more patient real world data was shared proactively by pharma. Embleema’s blockchain speeds up this process with patient buy-in, accelerating time to market new drugs.